Abstract
Respiratory syncytial virus (RSV) is a leading cause of respiratory illness and hospitalization but surveillance detects only a minority of cases. Wastewater surveillance could determine onset and extent of RSV circulation in the absence of sensitive case detection, but to date, studies of RSV in wastewater have been few. We measured RSV genomic RNA concentrations in wastewater solids from 176 US sites that provided samples at least three times per week during the 2022-2023 RSV season. Concentrations ranged from undetectable to 107 copies per gram dry weight (median = 103 cp/g). Wastewater RSV RNA concentration aggregated at state and national levels correlated with case positivity and hospitalization rates. Onset of RSV season was assessed for 14 states that collected data prior to the start of the RSV season. Wastewater and clinical surveillance identified onset of RSV during the same week in 3 states, whereas in 3 states, wastewater onset preceded clinical onset, and in 7 states, wastewater onset occurred after clinical onset. Wastewater concentrations generally peaked in the same week as hospitalization rates, but after case positivity rates peaked. Differences in onset and peaks in the wastewater versus clinical data may reflect inherent differences in the surveillance approaches.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the CDC Foundation and the Sergey Brin Family Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at https://www.cdc.gov/rsv/research/rsv-net/dashboard.html and https://www.cdc.gov/surveillance/nrevss/rsv/index.html
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos